AMOYTOP(688278)2025-02-25 08:50Financial Performance - Total revenue for 2024 reached CNY 281,715.82 million, a year-on-year increase of 34.13%[4] - Net profit attributable to shareholders was CNY 82,760.22 million, reflecting a growth of 49.00% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 82,696.48 million, up 42.73% year-on-year[6] - Basic earnings per share increased to CNY 2.03, representing a growth of 48.18%[4] Assets and Equity - Total assets at the end of the reporting period were CNY 305,041.48 million, a 29.47% increase from the beginning of the period[6] - Shareholders' equity attributable to the parent company rose to CNY 255,331.63 million, marking a 36.08% increase[6] - The company's net asset per share attributable to shareholders increased to CNY 6.28, a rise of 36.23%[5] Growth Drivers - The significant growth in revenue and profit was primarily driven by stable sales of the key product, Pegbivac, and ongoing management reforms[7] - The company emphasizes the importance of ongoing clinical research for hepatitis B treatment in driving product recognition and sales growth[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and subject to audit, with final figures to be disclosed in the annual report[9]